

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



30 October 2026

National Stock Exchange of India Limited
NSE Code: SUNPHARMA

BSE Limited
BSE Code: 524715

Outcome of the Board Meeting held today, i.e., 30 October 2026 - Conclusion

Further to our earlier intimation made today, [30 October 2026](#), this is to further inform that the Board of Directors of the Company, at its meeting held today, has, inter alia, approved the following:

Appointment of Statutory Auditors Pursuant to Mandatory Auditor Rotation

S R B C & CO LLP, Chartered Accountants ("SRBC"), the existing Statutory Auditors of the Company, shall complete its second consecutive term of five years at the conclusion of the Annual General Meeting ("AGM") of the Company for the financial year 2026-27. Accordingly, SRBC shall cease to hold office as the Statutory Auditors of the Company upon completion of its tenure, in accordance with the mandatory auditor rotation requirements prescribed under Section 139(2) of the Companies Act, 2013.

Based on the recommendation of the Audit Committee and subject to the approval of the shareholders of the Company, the Board has approved the appointment of Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W/W100739) as the Statutory Auditors of the Company for a term of five consecutive years, commencing from the conclusion of the AGM of the Company for the financial year 2026-27 and continuing until the conclusion of the AGM of the Company for the financial year 2031-32.

The disclosures required pursuant to Regulation 30 of the Listing Regulations, read with the applicable SEBI circulars, are enclosed herewith as [Annexure A](#).

The Board Meeting commenced at 10:45 AM (IST), was adjourned for a break, subsequently resumed, and concluded at 02:55 PM (IST).

For Sun Pharmaceutical Industries Limited

Anoop

Anjanikumar

Deshpande

(Anoop Deshpande)

Company Secretary and Compliance Officer

ICSI Membership No.: A23983

Digitally signed by
Anoop Anjanikumar
Deshpande
Date: 2026.10.30
15:15:38 +05'30'

Annexure A

Disclosure pursuant to Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Details
1	Name	Deloitte Haskins & Sells Chartered Accountants LLP, Firm Registration No. 117364W/W100739
2	Reason for change viz. appointment	Appointment as the Statutory Auditors of the Company consequent upon completion of the second consecutive term of the existing Statutory Auditors, S R B C & CO LLP, at the conclusion of the Annual General Meeting of the Company for the financial year 2026-27, in accordance with Section 139(2) of the Companies Act, 2013.
3	Effective date of appointment	From the conclusion of the Annual General Meeting of the Company for the financial year 2026-27, subject to the approval of the shareholders.
4	Term of appointment	Five consecutive years, commencing from the conclusion of the Annual General Meeting of the Company for the financial year 2026-27 and continuing until the conclusion of the Annual General Meeting of the Company for the financial year 2031-32, subject to the approval of the shareholders.
5	Brief profile	<p>Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W/W100739) is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India (“ICAI”) and is part of the Deloitte network of professional services firms. The firm has extensive experience in providing audit and assurance services to large listed and multinational companies across various sectors, including pharmaceuticals, life sciences and healthcare.</p> <p>The firm has significant experience in auditing leading companies in the pharmaceutical and healthcare sectors and is supported by a multidisciplinary team of audit, tax, technology and industry specialists.</p>
6	Disclosure of relationships between directors	Not applicable.